All In Biotech

NDA 216778 · Zydus Lifesciences

Zituvimet Xr

Metformin Hydrochloride, Sitagliptin · Oral · Dipeptidyl Peptidase 4 Inhibitor

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 18, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,828

753 Phase 3, 150 recruiting

FAERS reports

42

28 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 5, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 18, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
3 products under this application
  • ZITUVIMET XR · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN 100MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ZITUVIMET XR · METFORMIN HYDROCHLORIDE 500MG; SITAGLIPTIN 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ZITUVIMET XR · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.

All 2,828 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6
  • completed suicide4
  • dizziness4
  • nausea4
  • pain in extremity4
  • abnormal dreams3
  • diarrhoea3
  • malaise3
  • somnolence3
  • abdominal pain2
  • anxiety2
  • blood bilirubin increased2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20103
201113
201221
20251
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,495 on PubMed

Sponsor: Zydus Lifesciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.